Rane Holdings Limited (NSE:RANEHOLDIN)
India · Delayed Price · Currency is INR | Market Cap | 21.01B |
| Revenue (ttm) | 48.72B |
| Net Income (ttm) | 2.45B |
| Shares Out | n/a |
| EPS (ttm) | 171.51 |
| PE Ratio | 8.58 |
| Forward PE | n/a |
| Dividend | 38.00 (2.55%) |
| Ex-Dividend Date | Jul 29, 2025 |
| Volume | 18,165 |
| Average Volume | 13,898 |
| Open | 1,492.00 |
| Previous Close | 1,465.40 |
| Day's Range | 1,467.40 - 1,533.40 |
| 52-Week Range | 1,151.10 - 2,458.70 |
| Beta | 0.45 |
| RSI | 37.63 |
| Earnings Date | Aug 12, 2025 |
About Inozyme Pharma
Rane Holdings Limited, together with its subsidiaries, manufactures and markets automotive components for the transportation industry in India and internationally. The company offers steering and suspension systems comprising manual steering gears, steering linkages, suspension components, and hydraulic products; hydraulic power rack and pinion steering gear, power steering gear, power steering pump assemblies, and power steering fluid- power cruises; and intermediate shafts, electric power steering, solid steering energy absorbing and collapsi... [Read more]
Financial Performance
In 2024, Rane Holdings's revenue was 43.62 billion, an increase of 23.56% compared to the previous year's 35.30 billion. Earnings were 2.07 billion, an increase of 67.42%.
Financial StatementsNews
Rane Holdings acquires remaining 51% stake in joint venture Rane NSK Steering Systems
Rane Holdings has announced that it has acquired the remaining 51% equity stake in its joint venture, Rane NSK Steering Systems Private Limited (RNSS), from NSK Ltd., Japan. With this acquisition, RNS...